CPhI Announces 2014 Expert Industry Panel
CPhI Announces 2014 Expert Industry Panel
PR56644
AMSTERDAM, May 1, 2014/PRN=KYODO JBN/--
- Panel to contribute to Pharma Insights reports and second addition of the
CPhI annual report due to be launched at CPhI Worldwide 2014
Panel members for 2014:
- Prabir Basu, President at Pharma Manufacturing
- Girish Malhotra, President & Founder, Epcot International
[http://www.pharmaevolution.com/bloggers.asp#Girish_Malhotra ]
- Hedley Rees, Managing Director at PharmaFlow Ltd
- Ajaz Hussain, CSO & President Biotechnology at Wockhardt
- Sam Venugopal, Director in the Healthcare Practice at PWC
- William Botha, Consultant and Founder Interlean
- Emil Ciurczak, President at Doramaxx Consulting
- Dilip G Shah, CEO of Vision Consulting Group and a regulatory expert
- Vijay Shah, COO at Piramal Enterprises and pharma business lead
CPhI Worldwide [http://www.cphi.com ], organised by UBM Live, announces its
initial line-up of confirmed expert industry panel members for 2014 - building
on the huge success of the CPhI annual report launched at CPhI Worldwide in
October 2013.
(Logo: http://photos.prnewswire.com/prnh/20130723/629764-a )
This year's panel sees the return of nine thought leaders, with further
members joining imminently. Additionally, this year panel members will also be
utilising their market insights and analysis year-round in the CPhI Pharma
Insights series, which covers individual topics and developments across the
industry - including the recently launched R&D and manufacturing reports.
Expertise ranges from API and manufacturing efficiencies (Girish Malhotra)
to quality systems and supply chain activities (Sam Venugopal), with insights
also provided from some of the sectors' biggest names and innovators, like
Piramal's Vijay Shah. In addition, the panel features regulatory heavyweight
Ajaz Hussain of Wockhardt - renowned for coining the term PAT - who will lend
his expertise on establishing and improving drug regulation. Across supply
chain issues, the panel will leverage the knowledge of Hedley Rees, whilst
Prabir Basu, formerly of the National Institute for Pharmaceutical Technology
and Education (NIPTE), will focus on the industry's approach to innovation.
Regulatory expert, predominantly focussed on the Indian market, Dilip Shah
also returns, covering the intellectual property rules around innovation.
Emil Ciurczak, also previously a member of the FDA's PAT committee and
president of Doramaxx Consulting
[http://www.linkedin.com/search?search=&company=Doramaxx+Consulting&sortCriteria
=R&keepFacets=true&trk=prof-exp-company-name ] , draws up his expertise across
PAT, QbD and spectroscopy. Finally, William Botha, a respected trainer and
mentor in manufacturing, is also retuning to the panel; he is fluent in FDA
regulations, including GDP and GMP.
Last year's report examined a number of major issues and developments
across the industry including cost savings through QbD and PAT, to regulatory
challenges from a globalised industry, right through to the effect breakthrough
drugs like ADCs will have on overcoming future disease pathologies.
"Last year's report was a huge success with our experts, providing a
combined insight into the overall picture of the industry. What is interesting
this year is to see the progress the industry has made, and what new problems
or challenges there are. In the first annual report insights spanned a mixture
of practical manufacturing improvements, like single-use reactors and
continuous processing, mixed with regulatory risks and the future potential of
breakthrough drugs like ADCs and supply chain issues. Everything from
life-saving drugs to an open assessment of where industry risks lay, and
culminating in the new business model emerging- with increased partnerships,
innovation sharing and consolidation. Further, our experts offered conclusions
on the necessary techniques, technologies and a simplified regulatory approach
that will simultaneously increase safety and innovation," commented Chris
Kilbee, Group Director Pharma at CPhI.
The 2014 annual report will feature a collection of in-depth essays from
each panel member - with experts given carte blanche to prophesize how the
industry will look and operate in the future from both an economic and
practical perspective. Additionally, the CPhI Pharma Insights reports contain a
mixture of primary data (industry surveys) and expert comment on what these
findings show about the general direction of the industry and any issues they
feel need to be addressed.
CPhI is now in the later stages of assembling the panel's full line-up and
plans to announce all participants in the summer - with a few more global
heavyweights expected.
Kilbee added: "I am delighted that we have been able to source so many
leading figures from within the industry to take part in the panel, as
collectively they bring a huge amount of experience and insight. Already the
panel's knowledge spans pharmaceutical ingredients, manufacturing processes,
global supply chain issues and regulatory frameworks. One thing they all have
in common is a wealth of experience across international markets and a
practical approach to problem solving, which will be invaluable in postulating
future market dynamics."
For more information, please contact: cphi@ubm.com
About CPhI
CPhI drives growth and innovation at every step of the global
pharmaceutical supply chain from drug discovery to finished dosage. Through
exhibitions, conferences and online communities, CPhI brings together more than
100,000 pharmaceutical professionals each year to network, identify business
opportunities and expand the global market. CPhI hosts events in Europe, China,
India, Japan, Southeast Asia, Istanbul, Russia and South America and co-locates
with ICSE for contract services, P-MEC for machinery, equipment & technology,
InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an
online buyer & supplier directory at CPhI-Online.com.
For more information visit: http://www.cphi.com
The UBM Live annual schedule of Pharmaceutical events also includes CPhI
Russia and IPhEB (16-17 April, 2014 at the Lenexpo Exhibition Complex- St
Petersburg, Russia); CPhI, P-MEC and Innopack South East Asia (20-22 May, 2014
at the Jakarta International Expo- Jakarta, Indonesia); CPhI Istanbul (4-6
June, 2014, at the Lutfi Kirdar Convention and Exhibition Centre- Turkey);
CPhI, Hi and Fi, ICSE, P-MEC, BioPh and LabWorld China (26-28 June, 2014 at
SNIEC- Shanghai, China); CPhI South America (5-7 August 2014 at Expo Centre
Norte, Sao Paulo- Brazil); CPhI, ICSE Korea (2-3 September, 2014 at the COEX-
Seoul, South Korea); CPhI, ICSE, P-MEC and InnoPack Worldwide (7-9 October
2014, Paris Nord Villepinte- France); CPhI and P-MEC India (2-4 December, 2014
at the Bombay Exhibition Centre- Mumbai); CPhI, ICSE, P-MEC, BioPh and
Pharmatec Japan (22-24 April, 2015 at the Big Sight Exhibition Centre- Tokyo).
About UBM Live
UBM Live connects people and creates opportunities for companies across
five continents to develop new business, meet customers, launch new products,
promote their brands, and expand their market. Through premier brands such as
TFM&A, Internet World, IFSEC, MD&M, CPhI, Cruise Shipping Miami, the Concrete
Show, and many others, UBM Live exhibitions, conferences, awards programs,
publications, Websites, and training and certification programs are an integral
part of the marketing plans of companies across more than 20 industry sectors.
For media enquiries, please contact:
Alex Heeley or Tristan Jervis
De Facto Communications
T: +44(0)207-203-6745 / 6740
E: a.heeley@defacto.com / t.jervis@defacto.com
SOURCE: UBM Live
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。